| Assay ID | Title | Year | Journal | Article |
|---|
| AID709011 | Intrinsic clearance in dog hepatocytes assessed as parent compound disappearance at 1 uM per 10'6 cells | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709004 | Half life in Beagle dog at 27.2 uM/kg, po | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1062223 | Reduction of triglyceride AUC in human at 60 mg | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. |
| AID709028 | Inhibition of DGAT1 in rat liver microsomes | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709027 | Inhibition of DGAT1 in rat adipose tissue assessed as reduction in triacylglycerol synthesis | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709044 | Octanol/water partition coefficient, log D of the compound at pH 7.4 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709000 | Inhibition of muscarinic M2 receptor | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709021 | Inhibition of human ERG | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1546895 | Inhibition of recombinant FLAG-tagged human DGAT2 expressed in SF9 cells after 1 hr by TopCount assay | 2020 | Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
| The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. |
| AID708993 | Terminal half life in human at 1 to 20 mg | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709017 | Inhibition of CYP2D6 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709014 | Intrinsic clearance in human hepatocytes assessed as parent compound disappearance at 1 uM per 10'6 cells | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID708996 | Inhibition of plasma triacylglycerol excursion in 14 hrs fasted Han-Wistar rat at administered orally 2 hrs before bolus corn oil administration measured 1.5 hrs post corn oil challenge by oral lipid tolerance test relative to control | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709013 | Photostability stability by Hanau sun test | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709016 | Inhibition of CYP3A4 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1062226 | Tmax in human | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. |
| AID709043 | Volume of distribution in C57BL/6 mouse at 8.16 uM/kg, po or 5.4 uM/kg, iv | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709025 | Fraction unbound in rat plasma | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1062225 | Terminal half life in human | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. |
| AID709015 | Chemical stability in pH 1 to 10 buffer at 25 degC | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709033 | Inhibition of DGAT1 in human liver microsomes | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709003 | Oral bioavailability in Beagle dog at 27.2 uM/kg | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID708994 | Tmax in human at 1 to 20 mg | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709024 | Inhibition of DGAT1 in dog liver microsomes | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709006 | Clearance in Beagle dog at 27.2 uM/kg, po or 1.4 uM/kg, iv | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1062224 | Reduction of triglyceride AUC in human receiving 60% fat meal at >5 mg | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. |
| AID709005 | Volume of distribution in Beagle dog at 27.2 uM/kg, po or 1.4 uM/kg, iv | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709001 | Inhibition of FAAH | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709032 | Inhibition of DGAT1 in human adipose tissue assessed as reduction in triacylglycerol synthesis | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709008 | Clearance in Han-Wistar rat at 5.4 uM/kg, po or 2.7 uM/kg, iv | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709012 | Intrinsic clearance in mouse hepatocytes assessed as parent compound disappearance at 1 uM per 10'6 cells | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709009 | Oral bioavailability in C57BL/6 mouse at 8.16 uM/kg | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709038 | Apparent permeability from apical to basolateral side in MDCK cells at pH 7.4 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709041 | Solubility in 0.1 M phosphate buffer at pH 7.4 at 25 degC incubated for 24 hrs | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709010 | Half life in C57BL/6 mouse at 8.16 uM/kg, po | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID708999 | Inhibition of PDE10A1 receptor | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1546904 | Inhibition of recombinant FLAG-tagged human DGAT1 expressed in SF9 cells after 1 hr by TopCount assay | 2020 | Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
| The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. |
| AID709018 | Inhibition of CYP2C19 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1062220 | Reduction of triglyceride AUC in human relative to baseline | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. |
| AID709046 | Inhibition of human recombinant DGAT1 expressed in Sf9 cells by liquid scintillography | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709002 | Inhibition of ACAT at 10 uM | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709026 | Inhibition of DGAT1 in mouse liver microsomes | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709023 | Fraction unbound in mouse plasma | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709007 | Volume of distribution in Han-Wistar rat at 5.4 uM/kg, po or 2.7 uM/kg, iv | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709039 | Intrinsic clearance in rat hepatocytes assessed as parent compound disappearance at 1 uM per 10'6 cells | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709022 | Fraction unbound in dog plasma | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709031 | Inhibition of DGAT1 in human HuTu80 cells | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709030 | Inhibition of human DGAT2 by liquid scintillography | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID708995 | Inhibition of adipose triacylglycerol synthesis in 14 hrs fasted Han-Wistar rat assessed as decrease in ratio of [3H]palmitic acid incorporation in to TAG and DAG at 8 mg/kg administered orally and measured 1.5 hrs post dose relative to control | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709020 | Inhibition of CYP1A2 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709035 | Half life in Han-Wistar rat at 2.54 to 5.4 uM/kg, po | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709042 | Inhibition of human ACAT1 by liquid scintillography | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709029 | Inhibition of human ACAT2 by liquid scintillography | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709040 | Fraction unbound in human plasma at 37 degC by LC-UV/MS method based equilibrium dialysis method | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1062222 | Reduction of triglyceride AUC in human | 2013 | Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
| Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors. |
| AID709019 | Inhibition of CYP2C9 | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709047 | Clearance in C57BL/6 mouse at 8.16 uM/kg, po or 5.4 uM/kg, iv | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID708992 | Reduction in serum triglyceride level in human on standardized mixed meal diet at 5 mg UID | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID709034 | Oral bioavailability in rat | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1346154 | Human diacylglycerol O-acyltransferase 1 (2.3.1.- Acyltransferases) | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID709045 | Lipophilicity, log D of the compound at pH 7.4 by chromatographic method | 2012 | Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
| Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |